Pulmonary hypertension, despite advances in treatment, still has a poor prognosis, which is often associated with right heart failure, and for which pulmonary arterial hypertension (PAH) is a severe form. There is an urgent need to unravel the molecular mechanisms behind PAH and identify new targets, especially those involved in the remodeling process. The proliferation and resistance to apoptosis of pulmonary artery smooth muscle cells are key contributors to pulmonary vascular remodeling in PAH.
Researchers from Tikkunlev Therapeutics Inc. and the University of Utah have presented preclinical data on TLT-101, a gene therapy consisting of an adeno-associated virus serotype 9 (AAV9) vector encoding cardiac bridging integrator 1 (cBIN1) designed for the treatment of heart failure.
The lung and thrombosis may play a key role in cancer and metastasis progression, according to a collaborative study led by Cornell University scientists. In the nonmetastatic lung microenvironment of several cancer types, the development of a prothrombosis niche promotes metastasis formation through the release of small extracellular vesicles loaded with an integrin protein.
Med-tech companies focusing on cardiovascular diseases or neurological conditions, women’s health or robotic surgery, will find European investors willing to deploy capital into their stories. European venture capital firms are excited about the continuing innovation and opportunities in the sector.
Researchers from Morphic Therapeutic Inc. and affiliated organizations published data from a study that aimed to assess the potential of using arginylglycylaspartic acid (RGD) integrins for the treatment of cardiovascular diseases, such as pulmonary arterial hypertension (PAH).
Solid Biosciences Inc. is preparing for a sit-down with the U.S. FDA this year to discuss the firm’s results with the next-generation gene therapy SGT-003 for Duchenne muscular dystrophy (DMD).
Nearly six weeks after Johnson & Johnson paused the U.S. external evaluation of its Varipulse pulsed field ablation catheter to investigate several neurovascular events in initial cases, the med-tech giant resumed its limited market release with revised global instructions for use.
Dongkook Life Science Co. Ltd. (DKLS) priced a ₩18 billion (US$12.5 million) IPO on the Korea Exchange as South Korea’s first med-tech listing of the year.
Ziwig SAS, which leads the race for a simple diagnostic for endometriosis, picked up the pace with a fast-track reimbursement decision in France for its Endotest, the first saliva-based diagnostic assay for endometriosis.
Heart disease remains the leading cause of death worldwide, and developing new therapeutic approaches constitutes an urgent healthcare priority. Almost one-third of patients surviving myocardial infarction (MI) develop heart failure (HF), in part due to damage caused by the accumulation of dysfunctional mitochondria.
RSS
